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To investigate the prevalence of biallelic PKD1 and PKD2 variants underlying very early 
onset (VEO) polycystic kidney disease in a large international paediatric cohort referred for 
clinical indications over a 10-year period (2010-2020). 
Methods 
All samples were tested by Sanger sequencing and MLPA of PKD1 and PKD2 genes and/or 
a next-generation sequencing panel of 15 additional cystic genes including PKHD1 and 
HNF1B. Two patients underwent exome or genome sequencing. 
Results 
Likely causative PKD1 or PKD2 variants were detected in 30 infants with PKD-VEO, 16 of 
whom presented in utero. 21/30 (70%) had two variants with biallelic in trans inheritance 
confirmed in 16/21, 1 infant had biallelic PKD2 variants and 2 infants had digenic 
PKD1/PKD2 variants. There was no known family history of ADPKD in 13 families (43%) 
and a de novo pathogenic variant was confirmed in 6 families (23%). 
Conclusion 
We report a high prevalence of hypomorphic PKD1 variants and likely biallelic disease in 
infants presenting with PKD-VEO with major implications for reproductive counselling. The 
diagnostic interpretation and reporting of these variants however remains challenging using 
current ACMG/AMP and ACGS variant classification guidelines in PKD-VEO and other 
diseases affected by similar variants with incomplete penetrance. 
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Introduction 
Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic cause 
of kidney failure and usually presents in adult life 1. Very rarely, ADPKD can be diagnosed in 
utero or in infancy (up to the age of 18 months) with an often severe, very early onset (VEO) 
presentation associated with a reported high recurrence rate in subsequent pregnancies 2. 
 
The genetic mechanism underlying a VEO presentation has been shown to be related to 
reduced gene dosage 3 with biallelic PKD1 variants being the most consistent finding in 
several clinical case reports 4 5 6 7. In one study, digenic variants of PKD1 were reported with 
PKHD1 or HNF1B although these findings have not been confirmed in later studies 8. For 
instance, a French case series of prenatal onset patients in 41 families with known ADPKD 
reported 15 biallelic PKD1 variants but did not detect any trans-heterozygous variants in 
PKD2, PKHD1 and HNF1B 9.  
 
To determine the prevalence of these changes in an unselected cohort, we reviewed the 
results of all infants with a VEO presentation of polycystic kidney disease referred for 
diagnostic testing to a nationally accredited service laboratory in the UK over a 10-year 
period.  Our results confirm a high prevalence of biallelic PKD1 variants in VEO patients with 
an enrichment of ‘hypomorphic’ or reduced penetrance variants, often in heterozygosity with 
a pathogenic variant. In addition, we identified three cases of biallelic PKD2 variants or 
trans-heterozygous PKD1 and PKD2 variants. Importantly, a positive family history of 
ADPKD was only present in 57% of families with a high rate of de novo variants in 23% of 
families with available parental samples. Although these results have major implications for 
reproductive counselling, the diagnostic interpretation and reporting of these variants 
remains challenging using current ACMG/AMP and ACGS variant classification guidelines. 
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Materials and methods 
Study population 
A retrospective review of ADPKD genetic testing referrals from 2010–2020 was performed. 
All patients with a recorded age of onset of cystic kidneys from prenatal up to 18 months 
were selected from a large cohort of patients referred to the Sheffield Diagnostic Genetics 
Service (SDGS) for diagnostic testing.  Patients were selected by the date of birth at the time 
of referral and the specified age of onset of symptoms. 51 patients presenting below 18 
months of age were identified. Patients with a clinical history not suggestive of ADPKD or 
with an alternative genetic diagnosis were subsequently excluded. 
 
Methodology 
The methodology used and genes analysed for each infant are summarised in Table S1. 
Between 2010 to 2016, genetic testing was carried out by bidirectional Sanger sequencing 
of all coding exons and ±25bp intron/exon boundaries of the PKD1 and PKD2 genes. For the 
duplicated region of PKD1 (exons 1-33), PKD1-specific long-range PCR was performed 
followed by nested PCR and bi-directional sequencing to avoid the six highly homologous 
PKD1 pseudogenes (primer sequences in Table S2 and on request).  Sequencing was 
analysed using Mutation Surveyor® software with two independent checks and included a 
check for pseudogene contamination.  
 
From 2016 to 2018, long-range PCR and next-generation sequencing (NGS) of PKD1 and 
PKD2 using the IonTorrent Personal Genome Machine (PGM®) was performed. Long-range 
amplicons were pooled, purified, enzymatically fragmented (Ion Shear™ Plus), followed by 
end repair and adaptor ligation (Ion Plus Fragment Library Kit). Libraries were sequenced on 
316 chip with a minimum depth of coverage of x50 for exons ±5bp and x30 for introns 
between ±6-25bp. In-house bioinformatics analysis was performed using the BAM and a 
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VCF file generated by the IonTorrent software. The pipeline used sambamba to determine 
coverage and ANNOVAR to obtain HGVS nomenclature of variants and their consequences. 
Only effects on build hg19 transcripts NM_000297 and NM_001009944 were reported with 
all pseudogene bases masked as N. The results were filtered to remove known benign 
variants from an in-house manually curated polymorphism list. 
 
From 2018, testing evolved to the use of NGS on HiSeq 2000 with a minimum depth of 
coverage of x30 for exons ±5bp and x18 for introns between ±6-25bp. The designated cystic 
diagnostic panel comprised 17 genes associated with Polycystic Kidney Disease, Polycystic 
Liver Disease and Autosomal Dominant Tubulointerstitial Kidney Disease: PKD1, PKD2, 
DNAJB11, GANAB, PKHD1, DZIP1L, PRKCSH, SEC63, SEC61B, SEC61A1, LRP5, ALG8, 
UMOD, HNF1β, REN, TSC1 and TSC2. Library prep was performed using SureSelectXT 
library system (Agilent Technologies) and custom in-house designed probes. To aid read 
alignment to PKD1, the entire sequence of exons 1-33 including all intronic sequences was 
included in the SureSelect bait capture. Sequencing on the Illumina HiSeq using the HiSeq 
Rapid SBS Kit v2 performing 2 x 108 bp paired end reads. Bioinformatics analysis based on 
the open source ‘Best Practices’ workflow by the Broad Institute which includes BWA 
alignment of reads to human genome build hg19, identification of variants using 
HaplotypeCaller and annotation from dbSNP. Variants were subsequently filtered against in-
house benign polymorphism list.  
2 infants (cases 4 and 28) were tested using all three methods of long-range PCR and 
sanger sequencing, long-range PCR with NGS on PGM® and SureSelect capture with NGS 
on Illumina HiSeq2000. 2 infants (cases 22 and 25) were tested by both Sanger sequencing 
and SureSelect NGS. The results were fully concordant. 
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One family (case 7) underwent trio exome sequencing using an inheritance-based, gene-
agnostic approach. Another family (case 14) underwent trio whole genome sequencing via 
the UK 100,000 genomes project. Confirmation of the genotypes for case 7 and 14 and their 
parents was performed in our laboratory by long-range PCR and Sanger sequencing. 
 
Variant interpretation 
All sequence variants identified were assessed and scored according to American College of 
Medical Genetics / American Molecular Pathology (ACMG/AMP) 10 and the Association of 
Clinical Genetic Science (ACGS) best practice guidelines for the evaluation of pathogenicity 
and the reporting of sequence variants in clinical molecular genetics. Evaluation of 
pathogenicity included the use of Alamut® Visual 2.11 software, interrogation of available 
data from PKD mutation database (https://pkdb.mayo.edu), Human Gene Mutation 
Database (HGMD) Professional (https://portal.biobase-international.com/hgmd/pro) and the 
genome aggregation database for large exome and genome sequencing studies 
(https://gnomad.broadinstitute.org). Predicted evolutionary conservation in silico 
pathogenicity scores of missense variants were evaluated using REVEL11 (a meta-tool 
incorporating 13 evolutionary conservation in silico tools) using a cut-off of >0.5 for likely 
pathogenicity (Table S1). Variants with an ACMG variant classification score of class 3, 4 or 
5 were confirmed by independent Sanger sequencing including the use of long-range PCR 
for PKD1 exons 1-33. Dosage analysis was performed using MRC-Holland MLPA kits P351 
and P352. Variants with a classification of class 3-5 were reported to the clinician. For 
familial testing of known variants, two alternative primer sets were used for each amplicon to 
reduce the possibility of non-amplification of one allele due to single nucleotide variants 
(SNV) under the primer sites.  
 
Molecular modelling of PKD1 variants 
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PKD1 (6A70) 3D structures were modelled by SWISS-MODEL 12 and PHYRE2 13 automated 
protein homology modelling server 14. Because no experimental mutant PKD1 structures 
have been determined, we generated mutant structures by introducing individual missense 
variants in silico: missense variants were computationally modelled in UCSF Chimera 1.14 15 
by first swapping amino acids using optimal configurations in the Dunbrack rotamer library 16 
and by taking into account the most probable rotameric conformation of the mutant residue. 
All kinds of direct interactions: polar and nonpolar, favourable and unfavorable including 
clashes were analysed using contacts command in UCSF Chimera 1.14 15. In the output, the 
atom-atom contacts are listed in order of decreasing VDW (van der Waals) overlap: positive 
where the atomic VDW spheres are intersecting, zero if just touching, negative if separated 
by space. The evolutionary conservation score of each amino acid of PKD1 (6A70) was 
determined using the ConSurf algorithm, based on the phylogenetic relationships between 
sequence homologues 17 18. The structural impact of missense variants was also analysed 
using Missense3D and VarSite 19 20. Lollipop plots were generated using the 'lollipop' 
mutation diagram generator 21. 
 
Results 
Between 2010-2020, a total of 1371 referrals were received for diagnostic PKD genetic 
testing. The majority were from the UK, with 256 patients (18.7%) referred from 17 other 
countries. From this cohort, we identified 51 infants with clinical onset before 18 months of 
age (Figure 1). 15 infants had an alternate genetic diagnosis confirmed, most commonly 
biallelic PKHD1 pathogenic variants causing ARPKD (9 infants) or an HNF1B deletion (6 
infants). In 6 patients, no pathogenic variants were detected in PKD1 or PKD2 but no further 
testing of additional cystogenes was requested and no confirmation of the original clinical 
diagnosis could be obtained. 
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A total of 53 variants were found in the 30/36 infants, of which 47 were unique (43 PKD1 and 
4 PKD2) and 14 which had not been previously published (Table S1). 16/30 of these infants 
presented in utero with cysts and/or enlarged echogenic kidneys visible on antenatal 
ultrasound scans (Table 2). There was no known family history of ADPKD in 13 (43%) 
families. In 6 out of 26 (23%) families with available parental samples, we were able to 
confirm a de novo pathogenic variant. Twenty-one infants had two putative variants. In 16 
infants (73%) where parental samples were available, we confirmed biallelic in trans 
inheritance including 2 with de novo variants where phase was established by linkage with 
nearby variants (case 21) or NGS reads (case 12) (Figure S1). In 3 families, a de novo 
variant of unknown phase was detected. No parental samples were available for testing in 
the remaining 2 families. 
 
Biallelic variants (pathogenic and hypomorphic combination) 
16 infants had a pathogenic variant on one allele and a missense likely hypomorphic variant 
on the other allele. The pathogenic variant was inherited from an affected parent in 7 cases, 
from a parent with a positive family history in 2 cases, from a parent with no cysts and no 
family history in 1 case and was confirmed de novo in 4 cases. Parental samples were not 
available to confirm phase for 2 infants (cases 15 and 16). Inheritance of the likely 
hypomorphic variant was from an unaffected parent in all cases with parental samples 
available (27 parents with 0 cysts; 1 parent with 2 renal cysts; 2 families with unknown 
phase). 
 
Biallelic variants (two hypomorphic alleles)  
Five infants had 2 likely hypomorphic biallelic variants detected in trans (Figure 1, Figure 
S1). Two cases (case 18 and 19) were consanguineous and were homozygous for the likely 
variant. p.(Ser3037Leu) is novel but p.(Asn3188Ser) has been previously reported in a 
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different consanguineous family 4 and two other p.Asn3188 variants, p.(Asn3188Asp) and 
p.(Asn3188Ile) were reported in the French VEO-PKD cohort 9. Three other cases were 
compound heterozygous for two likely hypomorphic variants. One parent (case 18) had 3 
unilateral renal cysts (aged 26) while the remaining 9 parents had normal renal ultrasounds. 
Of interest, we detected 3 PKD1 variants in 1 infant (case 13) and biallelic PKD2 variants in 
another (case 5). 
 
Digenic variants 
Digenic PKD1 and PKD2 variants were found in 2 infants (case 8 and 16).  Case 8 has 
biallelic variants in PKD2 as well as a pathogenic variant in PKD1. Interestingly, the c.11713-
2A>T PKD1 pathogenic variant and the p.(Leu736_Asn737del) PKD2 likely pathogenic 
variant were both inherited from the affected mother, who was diagnosed incidentally in her 
20’s. However the fetus also inherited the p.(Val909Ile) PKD2 missense variant from the 
unaffected father. No additional cases with digenic inheritance of PKD1 or PKD2 variants 
and PKHD1 or HNF1B were detected in the 20 infants tested for additional cystogenes. 
 
Monoallelic variants (Genetically unresolved) 
Nine infants had a single PKD1 variant detected, 5 with cysts detected prenatally (Figure 1). 
5/9 infants had one pathogenic variant detected: 3 infants inherited a pathogenic variant 
from an affected parent; 1 infant had a de novo pathogenic variant and 1 pathogenic variant 
was detected in an infant with a family history of ADPKD but no parental samples available.  
The remaining 4 infants had one likely hypomorphic variant inherited from the unaffected 
parent, concordant with the family history. In 2 of these families, there was a family history of 
ADPKD but the causative pathogenic variant in the affected parent had not been detected, 
consistent with pick-up rate of approximately 90% in adult onset cohorts 22 9. Of the 9 infants 
with a single variant, 5/9 underwent further testing on an extended cystic panel. Consent for 
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further analysis was not available for the remaining 4 patients who had testing limited to 
PKD1 and PKD2 (3 cases) but also included PKHD1 in one case. 
 
In silico analysis 
Although the majority of hypomorphic variants detected were unique, 5 variants were 
recurrent, either in our study (Table 1) or previously reported. We performed in silico 
modelling of these recurrent variants using a recent cryoEM structure of truncated (aa3049-
4169) human PC1 complexed to PC2 14 (Figure 2), complementing this with NMR modelling 
of PLAT binding to several putative ligands including Ca2+, phosphatidylserine (PS), 
phosphatidylinositol-4-phosphate (PI4P) and b-arrestin 23 (Figure 3): p.(Arg3277Cys) Case 
1, 2, 28 and 4 5 9; p.(Arg3892His) Case 16 and 17; p.(Ile3167Phe) Case 10, 11 and 24; 
p.(Asn3188Ser) Case 19 and 4; p.(Glu4025Gly) Case 15 and 9. 
 
Of note, the first two variants lie within the signature PLAT domain (Ile3167, Asn3188). A 
third residue (Arg3277), lies adjacent to a unique altered residue (Arg3269), both located in 
the first intracellular loop linking PLAT and the second transmembrane domain (TM2). A 
fourth residue (Arg3892) lies in the linker between the TOP domain and the TM S2 helix, in 
close proximity to a non-recurrent change (Ala3959) in the TM S3 helix. The fifth residue 
(Glu4025) lies in the TM S5 helix (Figure 2). 
 
Three out of five variants were predicted to significantly alter the structure of the affected 
domain ie p.(Ile3167Phe), p.(Arg3277Cys), p.(Glu4025Gly) while the other two variants ie 
p.(Asn3188Ser) and p.(Arg3892His) were predicted to cause more subtle changes (Table 
S3). It was interesting to note that p.(Arg3892His) was inherited in trans with a second non-
recurrent variant p.(Arg3959Val) in one patient (case 17) as they are in close proximity 
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based on structural modelling despite being in different domains: the combination could 
have had a more profound effect in altering protein function (Figure 2). 
 
Missense3D analysis predicted that the p.(Ile3167Phe) substitution results in an altered 
surface cavity in the PLAT domain and could potentially affect a PS-binding pocket assigned 
in a previous NMR study that is important for membrane association (Figure 3A). 23 We 
noted that another altered residue Glu3121 (case 1) lies adjacent to Ile3167, forming part of 
the same membrane-interaction domain. Glu3121 is also part of the functional YEIL3123 AP2-
binding motif shown to mediate PC1 internalisation 23. Similarly, Gly3150 is localised in a 
protein interaction domain previously assigned by NMR 23 (Figure 3B). Asn3188 was not 
predicted to affect known ligand binding domains but could have a damaging effect on 
structure (Table S3). 
 
Discussion 
In this retrospective analysis of 30 infants with PKD-VEO referred over the past decade, we 
detected a high prevalence (70%) of biallelic variants, in particular PKD1 hypomorphic 
variants. These findings have important implications for reproductive genetic counselling 
since there is a 25% recurrence risk in subsequent pregnancies if both parents are 
heterozygous for each variant. Around 40% of the infants in our cohort had no previous 
known family history of ADPKD so the occurrence of a severely affected infant will be highly 
traumatic for clinically unaffected parents. In this context, we found a high incidence of de 
novo pathogenic variants (23%) as well as 5 infants with two hypomorphic variants in trans 
(17%) causing PKD-VEO. Our results confirm those from a French prenatal cohort, almost 
all with a positive family history, subjected to more limited genetic analysis (PKD1, PKD2, 
HNF1B, PKHD1) 9. Our detection rate however revealed twice the prevalence of biallelic 
PKD1 variants (70% v 37%) and a five-fold higher incidence of de novo PKD1 variants (23% 
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v 5%), reflecting the lower percentage of those with a positive family history in our cohort 
(60% v 95%). In contrast to a previous case series describing 8 pedigrees 8, we did not 
detect any infants trans-heterozygous for PKD1 and pathogenic variants in HNF1B or 
PKHD1 despite more extensive genetic testing in 20 infants (Figure 1). Other novel findings 
in our study were 3 cases of PKD-VEO due to biallelic PKD2 variants and/or trans-
heterozygosity for PKD1 and PKD2. 
 
Dosage effect and variability of phenotype severity 
There is an emerging consensus that cyst formation in ADPKD arises primarily through a 
dosage-dependent mechanism centred around PKD1 expression 25. In typical adult-onset 
disease, patients with PKD1 truncating pathogenic variants develop ESRD 15 years earlier 
than those with non-truncating pathogenic variants 26 27. Secondly, informative case reports 
of PKD-VEO infants with biallelic inheritance of missense ‘hypomorphic’ PKD1 variants in 
homozygosity (consanguineous) or heterozygosity with a pathogenic PKD1 truncating 
variant (in trans) demonstrate the importance of gene dosage in determining phenotypic 
severity 4 5 9. As observed in mouse studies 3, biallelic complete loss-of-function variants 
would be incompatible with live births and typically result in a high miscarriage rate or 
prenatal demise. Therefore, any likely ‘hypomorphic’ variants detected must retain partial or 
‘reduced’ protein function. The high frequency of missense or in-frame deletions detected in 
this study and in previous papers are in keeping with this conclusion. Thirdly, patients with 
pathogenic variants in two new ADPKD genes, GANAB and DNAJB11, have late-onset 
disease associated with lower but not absent PKD1 expression 28 29. Our findings of biallelic 
variants in PKD1 and PKD2 are consistent with a dosage effect and their likely function in a 
polycystin-1/polycystin-2 protein complex and common cystogenic pathway 30. Amongst our 
cohort of VEO cases, there was a range of phenotypic severity from severe, including 5 
infants with neonatal demise or TOP, to prenatal onset of cysts with no reported 
enlargement of kidneys or hypertension. A limitation of our study is that clinical follow-up for 
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all cases was not possible; therefore we cannot exclude a prenatal or neonatal diagnosis of 
ADPKD due to ascertainment bias in cases with a family history of ADPKD (cases 3, 16, 25 
and 27). 
 
Recurrent PKD1 hypomorphic variants 
We detected the PKD1 p.(Arg3277Cys) variant in 3 cases of PKD-VEO, being found in trans 
in 2 infants with a second hypomorphic PKD1 allele. In total, this variant has now been 
reported in 6 cases of PKD-VEO making it the most common recurrent PKD1 hypomorphic 
variant associated with this phenotype 4 5 9. We also detected the variants, PKD1 
p.(Arg3892His) and p.(Ile3167Phe), each in two cases of PKD-VEO. The p.(Ile3167Phe) 
variant has been reported in another family with 2 VEO cases 24. Although previously 
reported as a ‘likely’ pathogenic variant 4, it is frequent in population studies, has been found 
with a truncating pathogenic variant in several pedigrees (phase not established) and listed 
on the PKD mutation database as ‘indeterminate’, consistent with a hypomorphic role. 
p.(Arg3892His) has not been reported previously in association with PKD-VEO, although it 
has been detected in typical adult-onset patients 9 31. Although rarely detected in population 
studies, it is still present at a higher frequency than expected for fully penetrant PKD1 
alleles. These variants illustrate the difficulty in assigning pathogenicity to potential 
hypomorphic variants based solely on population frequency. 
 
The high prevalence of hypomorphic PKD1 variants in this context presents a challenge to 
their interpretation. Currently, we can only infer the likely pathogenicity of the majority of 
hypomorphic variants from their predicted ‘in silico’ effects on protein structure or function, 
evolutionary conservation of the altered residue, previous reported associations and low 
frequency in population databases. To confirm a true ‘hypomorphic effect’ on the PKD1 
protein, polycystin-1, functional studies will be required for individual variants. However, 
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there is currently no validated assay that is sufficiently sensitive, robust and readily 
accessible. In addition, the size and complexity of polycystin-1 makes this challenging to 
establish 32. The variant p.(Arg3277Cys) is the only PKD1 hypomorphic variant so far with 
unequivocal proven ‘reduced’ function in a genetically engineered mouse mutant (Pkd1 RC 
mouse) 3. Cellular studies have shown that p.(Arg3277Cys) leads to polycystin-1 misfolding, 
resulting in increased ER retention and reduced surface expression as has been shown for a 
few other PKD1 missense variants 23. Our use of structural modelling enabled some variants 
(although not all) to be further refined by their predicted effects on structure and function 
based on more recently available 3D structures of polycystin-1 and of PLAT. Not all domains 
currently have experimental structural information but as more structures of polycystin-1 
become available, this approach could be applied more systematically 19. 
 
Terminology, ACMG classification, and reporting 
Hypomorphic variants also cause difficulty with current terminology, ACMG classification and 
reporting as they do not function as classic ‘loss-of-function’ variants causing autosomal 
dominant disease. The terminology is confusing due to the variable language used which 
ranges from ‘hypomorphic’ 4, ‘reduced penetrance’ or ‘ultra-low penetrant’ 33. The ClinGen 
consortium Low Penetrance/Risk Allele Working Group has recently published guidelines on 
recommended terminology. For reduced penetrance variants, the use of the ACMG classes 
plus a quantitative descriptor i.e. “likely pathogenic, low penetrance” or “likely pathogenic, 
reduced penetrance” is recommended depending on sufficient quantitative penetrance 
estimates. These terms may be used for autosomal dominant disorders where the majority 
of carrier individuals do not develop features of the disease. However, the scenario for PKD1 
hypomorphic variants that cause cysts only when inherited in trans with another pathogenic 
or hypomorphic variant does not fall under this definition. We have therefore continued to 
use the term ‘hypomorphic’ throughout this publication classifying them by ACMG/ACGS 
guidelines but labelling the variants with ACMG class, adding H for likely hypomorphic allele. 
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Since hypomorphic alleles generally have no clinical phenotype in heterozygosity, they may 
be present in the general population at higher than expected frequencies. For example, the 
most common hypomorphic p.(Arg3277Cys) variant has been detected on 44 alleles in 
GnomAD (highest MAF 0.0005 or 0.05%).  The other likely hypomorphic variants detected in 
our cohort had a lower incidence than 44 alleles in gnomAD with 2 exceptions. 
p.(Thr2873Ile) is present on 57 alleles in GnomAD but was inherited in cis with the 
p.(Arg2191His) variant, detected in 37 alleles in GnomAD (case 13): the number of alleles 
with both variants present is not presently available in GnomAD but it is possible that the 
combination of both in cis is more deleterious. The c.9499A>T p.(Ile3167Phe) variant has 
been reported both as an ‘indeterminate’ variant and observed in trans in another family with 
2 cases of PKD-VEO 24. However it has been detected on 340 alleles in gnomAD including 2 
homozygotes (highest MAF 0.002). Nevertheless, structural modelling suggests that it is 
likely to be hypomorphic. 
 
Detection of a putative hypomorphic variant confirmed in trans with a pathogenic variant is 
usually considered highly suspicious and use of the ACMG variant guidelines PM3 (in trans) 
classifier can often add sufficient weighting to shift the classification into class 4 likely 
pathogenic. However, the latest Clinical Genomic Resource (ClinGen) sequence variant 
interpretation (SVI) recommendation for PM3 requires that PM2 is applied i.e. variants are 
sufficiently rare in large population studies such as GnomAD. The PM2 threshold for an 
autosomal dominant fully penetrant disease is 0, a situation very rarely applicable to PKD1 
hypomorphic variants. However, if the PM2 threshold for PKD1 hypomorphic variants was 
relaxed to a maximum of 45 alleles to align with p.(Arg3277Cys) frequency, the PM3 
classifier could be used more frequently. Thus the majority of putative hypomorphic variants 
can only be classified presently as “variants of uncertain clinical significance” using ACMG. 
The difficulties in reporting these variants is clearly exemplified by the conflicting 
classification of the p.(Arg3277Cys) variant on both ClinVar (reported as class 2 likely 
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benign (1), class 4 likely pathogenic (1) and class 5 pathogenic (1) 
[ https://www.ncbi.nlm.nih.gov/clinvar/variation/192320/ ] and the Human Gene Mutation 
Database (HGMD) [https://portal.biobase-international.com/hgmd/pro/all.php] where it is 
listed with conflicting support for pathogenicity. 
 
Hypomorphic or reduced penetrant variants are not unique to PKD1. Many examples are 
being reported in other diseases such as Maturity-Onset Diabetes of Young (MODY) eg 
HNF1A 34, RFX6 35, HNF4A 36, Parkinson’s disease (VPS35 37, LRRK2 38), Retinal dystrophy 
(ABCA4 39) and Joubert Syndrome (SUFU 40). Further clarification is therefore urgently 
needed to aid variant interpretation and reporting. As the price of next-generation 
sequencing has fallen dramatically and many laboratories are now using this technology, it is 
imperative that classic disease information sources are updated to reflect the prevalence of 
hypomorphic variants and particularly the alternate inheritance pattern for PKD1 and more 
rarely PKD2.  
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Summary of referrals for genetic testing in 51 infants presenting under 18 months of 
age between 2010-2020 and the main results. Of the 21 infants with biallelic variants, 20 




Structural modelling of PC1 hypomorphic variants 
(A) Lollipop plot showing missense variants relative to a schematic representation of the 
PC1 protein. Any position with a variant is indicated by a red circle, the grey bar represents 
the protein with the different amino acid positions (aa) and coloured boxes are specific 
functional domains. (B) Ribbon diagram of PC1 showing the representative missense variant 
residues in red. Dashed boxes correspond local impacts of variants on PC1 structure 14. 
 19 
Interactions are labelled as black dashed lines (Pseudobonds), H-bonds are labelled in 
purple and Inter-atomic distances are expressed in Å. 
 
Figure 3 
NMR model of the PC1 PLAT domain with surface mapping of specific ligand-binding 
residues. (A) Membrane-facing side showing phosphatidylserine, PS (stick), Ca2+ (orange 
sphere). Surface representation indicating residues binding PS (light blue) and b-arrestin1/2 
(pink). The key Ser3164 residue (red) which modulates PI4P and b-arrestin1/2 binding is 
indicated 23. (B) Cytoplasmic-facing surface of PLAT showing a predicted protein-interaction 
domain (deep blue). Several residues identified to be altered in this study are labelled 
(orange) and mapped onto this model ie E3121, I3167, G3150 and N3188. Note the close 
proximity of E3121 and 13167 to the same Ca2+-dependent PS binding pocket. E3121 also 






1. Ong AC, Devuyst O, Knebelmann B, Walz G, Diseases E-EWGfIK. Autosomal 
dominant polycystic kidney disease: the changing face of clinical management. 
Lancet. 2015;385(9981):1993-2002. 
2. Zerres K, Rudnik-Schoneborn S, Deget F. Childhood onset autosomal dominant 
polycystic kidney disease in sibs: clinical picture and recurrence risk. German 
Working Group on Paediatric Nephrology (Arbeitsgemeinschaft fur Padiatrische 
Nephrologie. J Med Genet. 1993;30(7):583-588. 
3. Hopp K, Ward CJ, Hommerding CJ, et al. Functional polycystin-1 dosage governs 
autosomal dominant polycystic kidney disease severity. The Journal of clinical 
investigation. 2012;122(11):4257-4273. 
4. Rossetti S, Kubly VJ, Consugar MB, et al. Incompletely penetrant PKD1 alleles 
suggest a role for gene dosage in cyst initiation in polycystic kidney disease. Kidney 
Int. 2009;75(8):848-855. 
5. Vujic M, Heyer CM, Ars E, et al. Incompletely penetrant PKD1 alleles mimic the renal 
manifestations of ARPKD. J Am Soc Nephrol. 2010;21(7):1097-1102. 
6. Losekoot M, Ruivenkamp CA, Tholens AP, et al. Neonatal onset autosomal dominant 
polycystic kidney disease (ADPKD) in a patient homozygous for a PKD2 missense 
mutation due to uniparental disomy. Journal of medical genetics. 2012;49(1):37-40. 
7. Ali H, Hussain N, Naim M, et al. A novel PKD1 variant demonstrates a disease-
modifying role in trans with a truncating PKD1 mutation in patients with autosomal 
dominant polycystic kidney disease. BMC Nephrol. 2015;16:26. 
8. Bergmann C, von Bothmer J, Ortiz Bruchle N, et al. Mutations in multiple PKD genes 
may explain early and severe polycystic kidney disease. Journal of the American 
Society of Nephrology : JASN. 2011;22(11):2047-2056 (Research Support, Non-U.S. 
Gov't). 
9. Audrezet MP, Corbiere C, Lebbah S, et al. Comprehensive PKD1 and PKD2 
Mutation Analysis in Prenatal Autosomal Dominant Polycystic Kidney Disease. J Am 
Soc Nephrol. 2016;27(3):722-729. 
10. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of 
sequence variants: a joint consensus recommendation of the American College of 
Medical Genetics and Genomics and the Association for Molecular Pathology. Genet 
Med. 2015;17(5):405-424. 
11. Ioannidis NM, Rothstein JH, Pejaver V, et al. REVEL: An Ensemble Method for 
Predicting the Pathogenicity of Rare Missense Variants. Am J Hum Genet. 
2016;99(4):877-885. 
12. Waterhouse A, Bertoni M, Bienert S, et al. SWISS-MODEL: homology modelling of 
protein structures and complexes. Nucleic Acids Res. 2018;46(W1):W296-W303. 
13. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJ. The Phyre2 web portal for 
protein modeling, prediction and analysis. Nat Protoc. 2015;10(6):845-858. 
14. Su Q, Hu F, Ge X, et al. Structure of the human PKD1-PKD2 complex. Science. 
2018;361(6406). 
15. Pettersen EF, Goddard TD, Huang CC, et al. UCSF Chimera--a visualization system 
for exploratory research and analysis. J Comput Chem. 2004;25(13):1605-1612. 
16. Shapovalov MV, Dunbrack RL, Jr. A smoothed backbone-dependent rotamer library 
for proteins derived from adaptive kernel density estimates and regressions. 
Structure. 2011;19(6):844-858. 
17. Ashkenazy H, Abadi S, Martz E, et al. ConSurf 2016: an improved methodology to 
estimate and visualize evolutionary conservation in macromolecules. Nucleic Acids 
Res. 2016;44(W1):W344-350. 
18. Landau M, Mayrose I, Rosenberg Y, et al. ConSurf 2005: the projection of 
evolutionary conservation scores of residues on protein structures. Nucleic Acids 
Res. 2005;33(Web Server issue):W299-302. 
 21 
19. Ittisoponpisan S, Islam SA, Khanna T, Alhuzimi E, David A, Sternberg MJE. Can 
Predicted Protein 3D Structures Provide Reliable Insights into whether Missense 
Variants Are Disease Associated? J Mol Biol. 2019;431(11):2197-2212. 
20. Laskowski RA, Stephenson JD, Sillitoe I, Orengo CA, Thornton JM. VarSite: Disease 
variants and protein structure. Protein Sci. 2020;29(1):111-119. 
21. Jay JJ, Brouwer C. Lollipops in the Clinic: Information Dense Mutation Plots for 
Precision Medicine. PLoS One. 2016;11(8):e0160519. 
22. Rossetti S, Consugar MB, Chapman AB, et al. Comprehensive molecular diagnostics 
in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 
2007;18(7):2143-2160. 
23. Xu Y, Streets AJ, Hounslow AM, et al. The Polycystin-1, Lipoxygenase, and alpha-
Toxin Domain Regulates Polycystin-1 Trafficking. J Am Soc Nephrol. 
2016;27(4):1159-1173. 
24. Mantovani V, Bin S, Graziano C, et al. Gene Panel Analysis in a Large Cohort of 
Patients With Autosomal Dominant Polycystic Kidney Disease Allows the 
Identification of 80 Potentially Causative Novel Variants and the Characterization of a 
Complex Genetic Architecture in a Subset of Families. Frontiers in Genetics. 
2020;11(464) (Original Research). 
25. Ong AC, Harris PC. A polycystin-centric view of cyst formation and disease: the 
polycystins revisited. Kidney Int. 2015;88(4):699-710. 
26. Cornec-Le Gall E, Audrezet MP, Chen JM, et al. Type of PKD1 mutation influences 
renal outcome in ADPKD. J Am Soc Nephrol. 2013;24(6):1006-1013. 
27. Heyer CM, Sundsbak JL, Abebe KZ, et al. Predicted Mutation Strength of 
Nontruncating PKD1 Mutations Aids Genotype-Phenotype Correlations in Autosomal 
Dominant Polycystic Kidney Disease. J Am Soc Nephrol. 2016;27(9):2872-2884. 
28. Porath B, Gainullin VG, Cornec-Le Gall E, et al. Mutations in GANAB, Encoding the 
Glucosidase IIalpha Subunit, Cause Autosomal-Dominant Polycystic Kidney and 
Liver Disease. Am J Hum Genet. 2016;98(6):1193-1207. 
29. Cornec-Le Gall E, Olson RJ, Besse W, et al. Monoallelic Mutations to DNAJB11 
Cause Atypical Autosomal-Dominant Polycystic Kidney Disease. Am J Hum Genet. 
2018;102(5):832-844. 
30. Ong ACM. Making sense of polycystic kidney disease. Lancet. 
2017;389(10081):1780-1782. 
31. Neumann HP, Jilg C, Bacher J, et al. Epidemiology of autosomal-dominant polycystic 
kidney disease: an in-depth clinical study for south-western Germany. Nephrol Dial 
Transplant. 2013;28(6):1472-1487. 
32. Cai Y, Fedeles SV, Dong K, et al. Altered trafficking and stability of polycystins 
underlie polycystic kidney disease. J Clin Invest. 2014;124(12):5129-5144. 
33. Cornec-Le Gall E, Torres VE, Harris PC. Genetic Complexity of Autosomal Dominant 
Polycystic Kidney and Liver Diseases. J Am Soc Nephrol. 2018;29(1):13-23. 
34. Misra S, Hassanali N, Bennett AJ, et al. Homozygous Hypomorphic HNF1A Alleles 
Are a Novel Cause of Young-Onset Diabetes and Result in Sulfonylurea-Sensitive 
Diabetes. Diabetes Care. 2020;43(4):909-912. 
35. Patel KA, Kettunen J, Laakso M, et al. Heterozygous RFX6 protein truncating 
variants are associated with MODY with reduced penetrance. Nat Commun. 
2017;8(1):888. 
36. Laver TW, Colclough K, Shepherd M, et al. The Common p.R114W HNF4A Mutation 
Causes a Distinct Clinical Subtype of Monogenic Diabetes. Diabetes. 
2016;65(10):3212-3217. 
37. Sharma M, Ioannidis JP, Aasly JO, et al. A multi-centre clinico-genetic analysis of the 
VPS35 gene in Parkinson disease indicates reduced penetrance for disease-
associated variants. J Med Genet. 2012;49(11):721-726. 
38. Sierra M, Gonzalez-Aramburu I, Sanchez-Juan P, et al. High frequency and reduced 
penetrance of LRRK2 G2019S mutation among Parkinson's disease patients in 
Cantabria (Spain). Mov Disord. 2011;26(13):2343-2346. 
 22 
39. Bauwens M, Garanto A, Sangermano R, et al. ABCA4-associated disease as a 
model for missing heritability in autosomal recessive disorders: novel noncoding 
splice, cis-regulatory, structural, and recurrent hypomorphic variants. Genet Med. 
2019;21(8):1761-1771. 
40. De Mori R, Romani M, D'Arrigo S, et al. Hypomorphic Recessive Variants in SUFU 
Impair the Sonic Hedgehog Pathway and Cause Joubert Syndrome with Cranio-




Table 1 Identified variants for each case including gene, cDNA & protein nomenclature, variant effect, ACMG classification and parent of origin 
along with relevant family history. 
 









1 PKD1 c.9361G>A p.(Glu3121Lys) Missense 4 Paternal No (both parents 
normal scans) 
PKD1 c.9829C>T p.(Arg3277Cys) Missense 4H Maternal 
2 PKD1 c.7483T>C p.(Cys2495Arg) Missense 4 Maternal Mother affected 
PKD1 c.9829C>T p.(Arg3277Cys) Missense 4H Paternal   
3 PKD1 c.8338G>T p.(Glu2780*) Nonsense 5 Paternal Father affected 
PKD1 c.9448G>A p.(Gly3150Ser) Missense 4H Maternal   
4 PKD1 c.8362_8363ins 
GCCAGCGAGGAGATCGTGGCCCAGGGCAAGCGCT 
p.(Ser2788Cysfs*45) Frameshift 5 Maternal Maternal FHx 
PKD1 c.5848G>A p.(Val1950Met) Missense 3H Paternal 
5 PKD2 c.817_818del p.(Leu273Valfs*29) Frameshift 5 Paternal Father affected 
PKD2 c.2593G>A p.(Val865Met) Missense 3 Maternal   
6 PKD1 5877_5882del p.(Ala1961_Gln1962del) In-frame 
deletion 
4 Maternal Maternal FHx 
PKD1 c.5785G>A p.(Glu1929Lys) Missense 3H Paternal 
7 PKD1 c.6487C>T p.(Arg2163*) Nonsense 5 Maternal Mother affected 
PKD1 c.9806G>A p.(Arg3269Gln) Missense 3H Paternal   
8 PKD1 c.11713-2A>T p.? Splice site 5 Maternal Mother affected 
PKD2 c.2208_2213del p.(Leu736_Asn737del) In-frame 
deletion 
4 Maternal   
PKD2 c.2725G>A p.(Val909Ile) Missense 3 Paternal   
9 PKD1 c.5482C>T p.(Gln1828*) Nonsense 5 Maternal Mother affected 
 2 
PKD1 c.9714C>T p.(=) ?Splicing 3H Paternal   
10 PKD1 c.755del p.(Pro252Argfs*38) Frameshift 5 Paternal Father affected 
PKD1 c.9499A>T p.(Ile3167Phe) Missense 3H Maternal   
11 PKD1 c.10326_10356del p.(Gly3443Serfs*20) Frameshift 5 de novo No 
PKD1 c.9499A>T p.(Ile3167Phe) Missense 3H Maternal   
12 PKD1 6793_6794dup p.(Arg2266Thrfs*49) Frameshift 5 de novo 
(in trans) 
No 
PKD1 c.6484C>T p.(Arg2162Trp) Missense 3H Maternal 
13 PKD1 c.11944C>T p.(Gln3982*) Nonsense 5 de novo No (2 small 
unilateral cysts in 
father aged 42) 
PKD1 c.6572G>A p.(Arg2191His) Missense 
3H Paternal 
PKD1 c.8618C>T p.(Thr2873Ile) Missense 
14 PKD1 c.7547G>A p.(Arg2516His) Missense 4 de novo No (both parents 
normal scans) 
PKD1 c.11003A>G p.(His3668Arg)   3H Maternal 
15 PKD1 c.6727_6728del p.(Gln2243Glufs*18) Frameshift 5 unknown Mother affected 
PKD1 c.12074A>G p.(Glu4025Gly) Missense 3H unknown   
16 PKD2   c.1081C>T p.(Arg361*) Nonsense 5 Unknown Father affected 
PKD1  c.11675G>A p.(Arg3892His) Missense 3H Unknown   
17 PKD1 c.11675G>A p.(Arg3892His) Missense 3H Paternal No 
PKD1 c.11876C>T p.(Ala3959Val) Missense 3H Maternal 
18 PKD1 c.9110C>T p.(Ser3037Leu) Missense 3 Paternal No (3 unilateral 
cysts in father age 
26) 
consanguineous 
PKD1 c.9110C>T p.(Ser3037Leu) Missense 3 Maternal 
19 PKD1 c.9563A>G p.(Asn3188Ser) Missense 4H Maternal No (parents 
normal scans; 
consanguinuous) 
PKD1 c.9563A>G p.(Asn3188Ser) Missense 4H Paternal 




PKD1 c.9222C>G p.(Asn3074Lys) Missense 3H Maternal 




PKD1 c.8998C>T p.(Arg3000Cys) Missense 3H Maternal   
22 PKD1 c.5014_5015del p.(Arg1672Glyfs*98) Frameshift 5 de novo No 
- - - - - -   
23 PKD1 c.12691C>T p.(Gln4231*) Nonsense 5 Maternal Mother affected 
- - - - - -   
24 PKD1 c.856_862del p.(Gly287*) Nonsense 5 Maternal Mother affected 
- - - - - -   
25 PKD1 c.7837_7839del p.(Leu2613del) In-frame 
deletion 
4 Maternal Mother affected 
- - - - - -   
26 PKD1 c.6842C>A p.(Ser2281Tyr) Missense 4 Unknown Father affected 
- - - - - - 
27 PKD1 c.12473T>C p.(Met4158Thr) Missense 3H Paternal Mother affected 
- - - - - - 
28 PKD1 c.9829C>T p.(Arg3277Cys) Missense 4H Paternal Father normal 
scan 
- - - - -   Mother affected 
29 PKD1 c.7928G>T p.(Arg2643Leu) Missense 3H Paternal No 
- - - - - -   
30 PKD1 c.1967T>A p.(Leu656Gln) Missense 3H Maternal No (parents 
normal scans) 
- - - - - - 
        
  
 1 
Table 2 Table showing clinical features of the 30 infants including age of onset/referral 
 
Case Age at clinical 
presentation 
Clinical information 
1 Prenatal (TOP) TOP due to bilateral enlarged echogenic kidneys; severe oligohydramnios. Hepatic ductal plate 
malformation on PM. 
2 Prenatal  Prenatal presentation 17/40. Severe neonatal PKD, multiple bilateral cysts, hypertension, mild 
pulmonary hypoplasia.  
3 Prenatal  Prenatal diagnosis of PKD; confirmed on postnatal scan. Bilateral. 
4 Prenatal (neonatal 
death) 
Enlarged kidneys, small bladder & oligohydramnios detected prenatally. Postnatal massively 
enlarged kidneys, respiratory insufficiency, severe hypertension and neonatal death. Sister has 
bilateral renal cysts. 
5 Prenatal (TOP) TOP. Fetal anomalies: enlarged bilateral echogenic kidneys, increased nuchal fold and 
prenasal oedema.  
6 Prenatal  Multiple renal cysts seen on prenatal scans; high BP. 
7 Prenatal (neonatal 
death) 
Deceased fetus, large cystic kidneys, anhydramnios, increased nuchal 
translucency, scalp oedema and large cisterna magna on PM. 
8 Neonatal Polycystic kidneys. Incubated due to pneumothorax at delivery. Renal USS more consistent 
with ARPKD. Hypertensive on medication. 
9 Referred age 2 
months 
Large cystic right kidney. Left kidney looks like PKD. 
10 Prenatal Abnormal antenatal ultrasound - large bright kidneys, reduced amniotic fluid. Postnatal renal 
impairment and hypertension. Relatively stable renal function- creatinine 76 (30-48). 
 2 
11 Aged 18m Polycystic kidneys diagnosed aged 1-2 years. Rapidly progressive renal failure; renal transplant 
aged 20. 
12 Prenatal Prenatal echogenic kidneys. Postnatally - multiple bilateral renal cysts identified. Normal growth 
and development. 
13 Age 18m Multiple bilateral renal cortical cysts. 
14 Referred aged 12 
months 
Bilateral renal cysts; enlarged kidneys. 
15 Neonatal Bilateral cystic kidneys at birth. Acute kidney failure, requiring ventilatiory support due to 
hypoplastic lungs. Massive kidneys compromising circulation.  
16 Neonatal Bilateral renal cysts detected postnatally. 
17 Prenatal Prenatal presentation; hypertension at birth, enlarged kidneys right 7.3 cm, left 7.6cm, diffusely 
echogenic with loss of cortico-medullary differentiation and a number of discrete cysts 
bilaterally. 
18 Prenatal Prenatal bilateral multicystic kidneys; bilateral hydronephrosis. Postnatal age 5months: both 
kidneys grossly enlarged, hyperechoic with multiple cysts (up to 8mm). 
19 Neonatal Hypertension at birth, scans showed echogenic kidneys. 
20 Age 18m Bilateral multicystic kidneys; atypical - no renal failure; high BP. 
21 Prenatal Polycystic kidneys detected prenatally; Postnatal poor renal function; Renal transplant aged 7. 
22 Age 12m  Diminished echogenicity and renal cysts with 1 macrocyst per kidney.  
23 Prenatal Prenatal bright kidneys; postnatal large kidneys with cysts; normal renal function age 2m. 
 3 
24 Referred age 16m Clinical diagnosis of PKD; Brother has bilateral kidney cysts age 6m.  
25 Prenatal Renal cysts detected prenatally. 
26 Prenatal Prenatal bilateral multicystic kidneys; postnatal bilateral multicystic & enlarged kidneys, 
hypertension. 
27 Prenatal Prenatal cysts, postnatally confirmed but diminished in size over time. 
28 Prenatal (neonatal 
death) 
Prenatal onset. Baby died shortly after birth. Variant identified also present in father (normal 
renal USS). 
29 Age 2m Multiple renal cysts age 2m;  subsequent USS showed increasing number of cysts & increase 
in kidney size. 
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Supplementary Figures and Tables 
Fig S1 The incidence of biallelic variants and their phase of transmission where available. (A) Bar chart showing the percentage of cases 
with a hypomorphic variant; (B) Bar chart showing phase of variants detected as determined by parental sequencing. PV: Pathogenic Variant; 
Hyp: Hypomorphic variant 
 
Table S1 Table showing methodology used for each case, which genes were analysed, ACMG classification and classification evidence 
used. The table includes the total number of alleles with the variant detected from gnomAD v2.2.1 as well as the highest minor allele frequency 
(MAF) recorded in one geographical/ethnic population. REVEL score is provided for missense variants only - this evolutionary conservation 
in silico meta-tool has a cut-off of >0.5 for predicted pathogenicity. References are provided for previously reported variants. 
Table S2 Table showing PKD1 long-range primer sequences. For exon 13-15F_LR a "wobble" base using IUPAC code was created to 
avoid non-amplification of one allele identified to cause allele drop out in 1 patient with adult-onset ADPKD. Nested primer sequences are 
available on request. 
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1 LR-PCR & 
Sanger seq 
PKD1/2 PKD1 c.9361G>A p.(Glu3121Lys) Missense 4 PM2/PS4_mod/PP4/PM3
_sup 
0 n/a 0.2 Cornec-Le 
Gall 2013 
PKD1 c.9829C>T p.(Arg3277Cys) Missense 4H PS3_mod/PS4_mod/PP1
_mod/PP3/PP4 
44 0.00045 0.6 Rossetti 
2009 
2 LR-PCR & 
Sanger seq 
PKD1/2 PKD1 c.7483T>C p.(Cys2495Arg) Missense 4 PM2/PS4_mod/PP3/PP4 0 n/a 0.9 Audrezet 
2012 
PKD1 c.9829C>T p.(Arg3277Cys) Missense 4H PS3_mod/PS4_mod/PP1
_mod/PP3/PP4 
44 0.00045 0.6 Rossetti 
2009 
3 LR-PCR & 
PGM NGS 
PKD1/2 PKD1 c.8338G>T p.(Glu2780*) Nonsense 5 PVS1/PM2/PS4_mod 0 n/a n/a Carrera 
2016 
PKD1 c.9448G>A p.(Gly3150Ser) Missense 4H PM2/PM3/PP3/PP4 2 0.000018 0.5 This study 
4 LR-PCR & 
Sanger seq 









Frameshift 5 PVS1/PM2 0 n/a n/a Gilbert 
2013 
PKD1 c.5848G>A p.(Val1950Met) Missense 3H PM2/PM3/PP4 3 0.00006 0.4 Bataille 
2011 
5 LR-PCR & 
Sanger seq 
PKD1/2 PKD2 c.817_818del p.(Leu273Valfs*29) Frameshift 5 PVS1/PM2/PS4_mod 0 n/a n/a Rossetti 
2003 









4 PM2/PM4/PP1_sup/PP4 0 n/a n/a This study 
PKD1 c.5785G>A p.(Glu1929Lys) Missense 3H PM2/PM3/PP4 2 0.000057 0.2 This study 
7 Exome Exome PKD1 c.6487C>T p.(Arg2163*) Nonsense 5 PVS1/PM2/PS4_mod 0 n/a n/a Rossetti 
2001 
PKD1 c.9806G>A p.(Arg3269Gln) Missense 3H PM2/PM3/PP4 1 0.000015 0.4 Kinoshita 
2016 











26 0.00017 n/a Stekrova 
2009 




9 LR-PCR & 
PGM NGS 
PKD1/2 PKD1 c.5482C>T p.(Gln1828*) Nonsense 5 PVS1/PM2/PS4_mod 0 n/a n/a Rossetti 
2002 




PKD1/2 PKD1 c.755del p.(Pro252Argfs*38) Frameshift 5 PVS1/PM2/PS4_sup 0 n/a n/a Kurashige 
2015 
PKD1 c.9499A>T p.(Ile3167Phe) Missense 3H PS4_sup/PM3/PP3/PP4 340 0.0021 0.5 Rossetti 
2002 







p.(Gly3443Serfs*20) Frameshift 5 PVS1/PM2/PM6 0 n/a n/a This study 






PKD1 c.6793_6794dup p.(Arg2266Thrfs*49) Frameshift 5 PVS1/PM2/PM6/PS4_sup 0 n/a n/a This study 




13 LR-PCR & 
Sanger seq 
PKD1/2 PKD1 c.11944C>T p.(Gln3982*) Nonsense 5 PVS1/PM2/PM6 0 n/a n/a Rossetti 
2007 




PKD1 c.8618C>T p.(Thr2873Ile) Missense 57 0.00069 0.2 This study 









PKD1 c.6727_6728del p.(Gln2243Glufs*18) Frameshift 5 PVS1/PM2/PS4_mod 0 n/a n/a Rossetti 
2001 





PKD2   c.1081C>T p.(Arg361*) Nonsense 5 PVS1/PM2/PS4_mod 0 n/a n/a This study 
PKD1  c.11675G>A p.(Arg3892His) Missense 3H PS4_sup/PM3_sup/PP3/P
P4 
17 0.00096 0.8 Neumann 
2013 





PKD1 c.11675G>A p.(Arg3892His) Missense 3H PS4_sup/PM3_sup/PP3/P
P4 
17 0.00096 0.8 Neumann 
2013 
PKD1 c.11876C>T p.(Ala3959Val) Missense 3H PP3/PP4 0 n/a 0.5 This study 




PKD1 c.9110C>T p.(Ser3037Leu) Missense 3H PM2/PP4 1 0.000015 0.4 This study 
PKD1 c.9110C>T p.(Ser3037Leu) Missense 3H 













PKD1  c.2878G>A p.(Gly960Ser) Missense 3H PS4_mod/PM5_sup/PP3/
PP4 
2 0.00011 0.9 Neumann 
2013 
PKD1 c.9222C>G p.(Asn3074Lys) Missense 3H PM2/PM6/PP4 4 0.00015 0.3 Bergmann 
2011 





PKD1 c.3739A>G p.(Met1247Val) Missense 3H PM2/PM6/PP4 0 n/a 0.4 This study 
PKD1 c.8998C>T p.(Arg3000Cys) Missense 3H PM3/PS4_sup/PP4 4 0.00011 0.2 Bullich 
2018 







PKD1 c.5014_5015del p.(Arg1672Glyfs*98) Frameshift 5 PVS1/PS4_mod/PM6 0 n/a n/a Watnick 
1999 
- - - - - 




PKD1/2 PKD1 c.12691C>T p.(Gln4231*) Nonsense 5 PVS1/PM2/PS4_mod 0 n/a n/a Stekrova 
2009 
- - - - -           
24 LR-PCR & 
Sanger seq 
PKD1/2 PKD1 c.856_862del p.(Gly287*) Nonsense 5 PVS1/PM2/PS4_mod 0 n/a n/a O'Brien 
2012 
- - - - -           











0 n/a n/a Bouba 
2001 





PKD1 c.6842C>A p.(Ser2281Tyr) Missense 4 PS4_sup/PM2/PM5/PP3/
PP4 
0 n/a 0.9 This study 
- - - - - 
   
    








- - - - -           







PKD1 c.9829C>T p.(Arg3277Cys) Missense 4H PS3_mod/PS4_mod/PP1
_mod/PP3/PP4 
44 0.00045 0.6 Rossetti 
2009 





PKD1 c.7928G>T p.(Arg2643Leu) Missense 3H PM5/PP3/PP4 19 0.00063 0.6 Garcia-
Gonzalez 
2007 
- - - - -           








- - - - -           
             























Predicted    
Protein Change 
ConSurf 













Polarity Charge Chemical HI ΔΔG ΔΔSVib DP Prediction 
p.Glu3121Lys 8 P/P -/+ acidic/basic -3.5/-3.9 -1.065 -0.212 0.266 -1.681 -0.03 Neutral 1.14 Favoured 0.082 1 -2.32 1.915 
p.Gly3150Ser 9 NP/P N/N aliphatic/hydroxyl -0.4/-0.8 -0.371 0.752 -0.94 -1.062 -0.78 Neutral 1.34 Neutral 0 1 -3.65 3.085 
p.Ile3167Phe 6 NP/NP N/N aliphatic/aromatic 4.5/2.8 -0.353 -0.214 0.268 -0.696 -0.54 Damaging 1.13 Neutral 0.026 0.996 -2.65 2.45 
p.Asn3188Ser 9 P/P N/N amide/hydroxyl -3.5/-0.8 -0.344 -0.558 0.697 -0.497 -1.7 Neutral 0.66 Favoured 0 1 -4.68 2.96 
p.Arg3269Gln 8 P/P +/N basic/amide -4.5/-3.5 0.105 -0.35 0.438 -0.714 -1.78 Damaging 1.19 Favoured 0 1 -3.54 3.425 
p.Arg3277Cys 9 P/NP +/N basic/sulfur -4.5/2.5 -1.275 -0.278 0.348 -1.093 -1.82 Neutral 1.71 Unfavoured 0 1 -7.41 2.97 
p.His3668Arg 8 P/P +/+ basic/basic -3.2/-4.5 -0.181 -0.156 0.195 -1.116 0.22 Neutral 0.81 Neutral 0.221 1 -3.24 1.895 
p.Arg3892His 5 P/P +/+ basic/basic -4.5/-3.2 -0.825 -0.039 0.049 -1.684 0.43 Neutral 1.45 Neutral 0.143 1 -1.93 2.585 
p.Ala3959Val 8 NP/NP N/N aliphatic/aliphatic 1.8/4.2 -0.102 0.317 -0.397 -0.63 -1.03 Neutral 0.75 Neutral 0.007 1 -1.72 2.62 
p.Glu4025Gly 8 P/NP -/N acidic/aliphatic -3.5/-0.4 -0.655 -0.353 0.441 -0.953 -1.55 Neutral 0.75 Unfavoured 0.003 1 -4.05 2.7 
 
NP nonpolar, P polar, N neutral, HI Hydropathy index, ConSurf conservation scores (9 - conserved, 1 - variable), ΔΔG in kcal/mol (change in folding free energy between wild-type and mutant 
structures, ΔΔG ≥ 0 as stabilizing and ΔΔG < 0 as destabilizing), ΔΔSVib in kcal.mol-1.K-1 (Vibrational Entropy difference between wild-type and mutant structure, ΔΔSVib ≥ 0 as increase of molecule 
flexibility and ΔΔSVib < 0 as decrease of molecule flexibility), DP Disease propensity value (normalized ratio of the number of disease-to-natural variants of a given type), SIFT (Score 0.0 to 0.05 is 
deleterious), PolyPhen-2 (Score 0.85 to 1.0 is predicted to be damaging), PROVEAN protein variation effect analyser (Score <-2.5 is deleterious), MA Mutation Assessor (Functional impact combined 
score). 
 
 
